Aspira Pathlab & Diagnostics Ltd

ASPIRA

Watchlist

AI Mode

‌

Market Cap

₹ 69 Cr

P/E

28.56

‌

‌
‌

‌

‌
‌

Investment Checklist

How to read checklist?

Performance

STEADY PERFORMER

Valuation

REASONABLE

Growth

SLUGGISH

Profitability

MODERATE MARGIN

Technicals

Bullish

Risk

MODERATE RISK

Investment Checklist

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

Price

PE Ratio

Price

‌

Overview

Detailed Summary

Aspira Pathlab & Diagnostics Limited (ASDL) is a leading pathology specialist in India, offering a wide range of diagnostic services.

The company operates with an asset-light model but faces high operational costs which it is working to optimize.

Aspira has a strong presence in Maharashtra and aims to strengthen its regional footholds before scaling operations.

The company is adopting new technologies like chatbots and patient engagement platforms to enhance customer experience.

Sector

Healthcare

Industry

Diagnostic Services

Market Cap

69 Cr

Volatility

Low Risk

P/E Ratio

28.6

Industry P/E

48.3

PEG Ratio

0.2

P/B Ratio

9.5

52W High

106.78

52W Low

50.49

Sales CAGR

66.67%

4.03%

21.19%

10Y

—

Profit CAGR

175.66%

-22.54%

—

10Y

61.69%

ROE

TTM

16.62%

-1.96%

9.17%

10Y

-16.71%

ROCE

TTM

13.17%

1.02%

10.84%

10Y

-6.22%

Technicals

‌

Forecasts

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
INVICTA	88.00	111 Cr	23.59	2.17	0.00	35.97	39.64	0.00
ASPIRA	66.96	69 Cr	28.56	9.47	0.00	16.62	13.17	13.75
NIDAN	18.95	26 Cr	13.44	0.39	0.00	3.32	6.57	2.69
GIANLIFE	8.89	9 Cr	—	0.48	0.00	-0.19	2.13	-0.22
CTLLAB	39.50	9 Cr	25.99	1.02	0.00	5.19	7.65	4.22
DLCL	17.50	8 Cr	25.36	0.76	0.00	4.53	3.40	2.92
DOLPHMED	2.61	4 Cr	—	0.39	0.00	-0.26	-0.12	-0.16

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Jun 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Sales	2.60	3.82	4.64	6.18	5.41	5.78	5.25
Expenses	3.03	4.02	4.37	4.90	4.73	4.81	4.52
Operating Profit	-0.43	-0.20	0.27	1.28	0.68	0.97	0.73
OPM %	-16.54	-5.24	5.82	20.71	12.57	16.78	13.90
Other Income	0.10	0.08	0.15	0.08	0.02	0.09	0.06
Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation	0.39	0.38	0.38	0.36	0.39	0.37	0.37
Profit Before Tax	-0.72	-0.50	0.05	0.99	0.31	0.68	0.42
Tax %	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit	-0.72	-0.50	0.05	0.99	0.31	0.68	0.42
EPS in Rs	-0.70	-0.49	0.05	0.96	0.30	0.66	0.41

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2024	Mar 2025
Sales	13	22
Expenses	14	18
Operating Profit	-1.19	3.52
OPM %	-8.99	16.02
Other Income	0.42	0.34
Interest	0.37	0.35
Depreciation	1.54	1.49
Profit Before Tax	-2.67	2.02
Tax %	0.00	0.00
Net Profit	-2.67	2.02
EPS in Rs	—	1.97
Dividend Payout %	0.00	0.00

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2024	Mar 2025
Equity Capital	10	10
Reserves	-0.15	1.87
Borrowings	2.78	3.20
Other Liabilities	1.78	2.10
Total Liabilities	15	17
Fixed Assets	6.79	6.53
CWIP	0.00	0.00
Investments	0.00	0.08
Other Assets	7.92	11
Total Assets	15	17

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2024	Mar 2025
Cash from Operating Activity	1.05	1.83
Cash from Investing Activity	0.14	0.12
Cash from Financing Activity	-0.95	-0.99
Net Cash Flow	0.24	0.95

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Mar 2023	Jun 2023	Aug 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Promoters	19.47%	19.37%	19.37%	18.90%	18.90%	18.72%	18.72%	18.55%	18.55%	18.39%	18.39%	18.39%
FIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
DIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Public	80.53%	80.63%	80.63%	81.10%	81.10%	81.28%	81.28%	81.45%	81.45%	81.61%	81.61%	81.61%
Total Shareholders	1,300	1,371	1,371	1,406	1,351	1,512	1,695	1,706	1,593	1,741	1,770	1,755

Market Transactions

Date	Party	Category	Type	Avg Price (₹)	Total Value (₹)	Quantity	Percent Traded
Oct 09, 2025	Divya kanda	Bulk	Buy	59.56	0.31 Cr	52,130	0.50
Oct 09, 2025	Divya kanda	Bulk	Sell	61.97	0.09 Cr	14,721	0.14
Oct 06, 2025	Devji deyat nanda	Bulk	Sell	75.26	0.68 Cr	90,000	0.87
Aug 25, 2025	Adequate real trade llp	Bulk	Buy	58.99	0.42 Cr	72,000	0.69
Jun 02, 2025	Jay arvind bhanushali	Insider - Promoters Immediate Relative	Acquisition	51.55	0.00 Cr	150	0.00
May 28, 2025	Jay arvind bhanushali	Insider - Promoters Immediate Relative	Acquisition	54.50	0.00 Cr	250	0.00
May 28, 2025	Jay arvind bhanushali	Insider - Promoters Immediate Relative	Acquisition	54.00	0.00 Cr	479	0.00
May 28, 2025	Jay arvind bhanushali	Insider - Promoters Immediate Relative	Acquisition	55.00	0.00 Cr	150	0.00
May 28, 2025	Jay arvind bhanushali	Insider - Promoters Immediate Relative	Acquisition	54.00	0.02 Cr	3,250	0.03
Mar 25, 2025	Paresh bhanji bhanushali	Insider - Promoter	Disposal	107.00	0.00 Cr	1	0.00

Projection

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

Documents

Presentations

Concalls

Reports

Presentations

No documents found!

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

AI Mode

Oscillators

BearishNeutralBullish

Neutral

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bullish

Bearish

Neutral

Bullish

Moving Averages

BearishNeutralBullish

Bullish

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bullish

Bearish

Neutral

Bullish

Overview

Detailed Summary

Aspira Pathlab & Diagnostics Limited (ASDL) is a leading pathology specialist in India, offering a wide range of diagnostic services.

The company operates with an asset-light model but faces high operational costs which it is working to optimize.

Aspira has a strong presence in Maharashtra and aims to strengthen its regional footholds before scaling operations.

The company is adopting new technologies like chatbots and patient engagement platforms to enhance customer experience.

Sector

Healthcare

Industry

Diagnostic Services

Market Cap

69 Cr

Volatility

Low Risk

P/E Ratio

28.6

Industry P/E

48.3

PEG Ratio

0.2

P/B Ratio

9.5

52W High

106.78

52W Low

50.49

Sales CAGR

66.67%

4.03%

21.19%

10Y

—

Profit CAGR

175.66%

-22.54%

—

10Y

61.69%

ROE

TTM

16.62%

-1.96%

9.17%

10Y

-16.71%

ROCE

TTM

13.17%

1.02%

10.84%

10Y

-6.22%

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
INVICTA	88.00	111 Cr	23.59	2.17	0.00	35.97	39.64	0.00
ASPIRA	66.96	69 Cr	28.56	9.47	0.00	16.62	13.17	13.75
NIDAN	18.95	26 Cr	13.44	0.39	0.00	3.32	6.57	2.69
GIANLIFE	8.89	9 Cr	—	0.48	0.00	-0.19	2.13	-0.22
CTLLAB	39.50	9 Cr	25.99	1.02	0.00	5.19	7.65	4.22
DLCL	17.50	8 Cr	25.36	0.76	0.00	4.53	3.40	2.92
DOLPHMED	2.61	4 Cr	—	0.39	0.00	-0.26	-0.12	-0.16